SC denies patent to Novartis's cancer drug Glivec

Swiss pharma major Novartis AG on Monday lost a seven-year long legal battle for getting its blood cancer drug Glivec patented in India and to restrain Indian companies from manufacturing generic......

Big Pharma waits nervously on Glivec patent verdict

Global drugmakers, battered by recent intellectual property decisions in India, are girding for a landmark court ruling next week with broad consequences for their ability to sell lucrative......

India rejects patent to Glivec's second variant

In yet another setback to Swiss drug multinational Novartis AG, the Indian patent office has rejected its application to secure a patent for an alfa crystal form of its blockbuster cancer medicine,......

Novartis optimistic despite Glivec setback

Swiss pharmaceutical giant Novartis is buoyant about growth prospects and further protection of intellectual property rights in India, despite the setback it suffered in the patent dispute for its......